PTSD
Conditions
Keywords
Transcranial Magnetic Stimulation
Brief summary
Testing a Causal Model of Cognitive Control Deficits in Posttraumatic Stress Disorder (PTSD)
Detailed description
The purpose of the present study is to examine the effects of transcranial magnetic stimulation (TMS) on cognitive control among individuals with posttraumatic stress disorder (PTSD).
Interventions
PROCEDURETranscranial Magnetic Stimulation (TMS)
Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
Sponsors
Florida State University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Each participant will receive stimulation to two brain areas (right dorsolateral prefrontal cortex and vertex) in a counterbalanced order.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Over 18 years of age * Endorse lifetime exposure to at least one Criterion A traumatic event * Report clinically significant posttraumatic stress disorder (PTSD) symptoms (score of ≥ 33 on the PTSD Checklist for DSM-5 \[PCL-5\]).
Exclusion criteria
* Endorse medical contraindication for neuromodulation (e.g., ferrous metal in head, seizure disorder, brain tumor, stroke, aneurysm, multiple sclerosis, etc.) * Report an unstable medical condition or any current medical condition that precludes safe participation in the trial (e.g., unstable metabolic abnormality, unstable angina, etc.) * Report any history or diagnosis of dementia or other cognitive disorder, which may interfere with engagement * Report any history or diagnosis of Severe Traumatic Brain Injury * Report any history or diagnosis of Schizophrenia, Schizoaffective Disorder, Delusional Disorder or other psychotic illness, which precludes safe participation in the trial * Report a primary obsessive-compulsive disorder (OCD) diagnosis * Report an active substance use disorder (within last 3 months) or any current substance use that precludes safe participation in the trial * Report suicide risk that precludes safe participation in the trial, defined as clinical impression that the participant is at significant risk for suicide (i.e., greater than moderate level of suicide risk, in accordance with the Joiner et al. (1999) suicide risk framework) * Report an inability to stop taking any medication that significantly lowers the seizure threshold (e.g., tricyclic antidepressants, clozapine, etc.) * Report a current, planned, or suspected pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Performance on emotional working memory task | 5 hours | Accuracy and reaction time on a task measuring working memory in the presence of trauma-related distractor images |
Countries
United States
Outcome results
None listed